Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Treasury Shares (2016 - 2025)

Sangamo Therapeutics has reported Treasury Shares over the past 15 years, most recently at $5.6 million for Q4 2025.

  • Quarterly results put Treasury Shares at $5.6 million for Q4 2025, down 48.79% from a year ago — trailing twelve months through Dec 2025 was $5.6 million (down 48.79% YoY), and the annual figure for FY2025 was $5.6 million, down 48.79%.
  • Treasury Shares for Q4 2025 was $5.6 million at Sangamo Therapeutics, down from $11.0 million in the prior quarter.
  • Over the last five years, Treasury Shares for SGMO hit a ceiling of $11.0 million in Q4 2024 and a floor of $3.1 million in Q4 2021.
  • Median Treasury Shares over the past 5 years was $5.6 million (2025), compared with a mean of $6.2 million.
  • Biggest five-year swings in Treasury Shares: surged 82.11% in 2024 and later plummeted 48.79% in 2025.
  • Sangamo Therapeutics' Treasury Shares stood at $3.1 million in 2021, then soared by 67.02% to $5.2 million in 2022, then increased by 15.43% to $6.1 million in 2023, then surged by 82.11% to $11.0 million in 2024, then crashed by 48.79% to $5.6 million in 2025.
  • The last three reported values for Treasury Shares were $5.6 million (Q4 2025), $11.0 million (Q4 2024), and $6.1 million (Q4 2023) per Business Quant data.